Method and improved pharmaceutical composition for enhancing transdermal delivery of PDE-5 inhibitor
AssigneeTritech Biopharmaceuticals Co., Ltd.
InventorsYee-Chien Liu, Pei-Ling Wu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of an agent that enhances transdermal delivery of a PDE-5 inhibitor. More particularly, the present disclosure provides improved method and composition that promotes transdermal delivery of a PDE-5 inhibitor for the treatment of the PDE-5 mediated conditions and/or diseases.
Claims8
A transdermal pharmaceutical composition comprising an effective amount of vardenafil or a pharmaceutically acceptable salt thereof;
- and an enhancer consists of cocamidopropyl betaine, sodium lauroamphoacetate, quaternium-60, isostearamidopropyl morpholine lactate, and dipropylene glycol;
- wherein vardenafil and the enhancer are present in a ratio from about 20:1 to 2:1 by weight in the transdermal pharmaceutical composition, and the transdermal pharmaceutical composition is in the form of a solution, a gel or a patch;
- and
- a pharmaceutically acceptable excipient.
A method for enhancing transdermal delivery of vardenafil in a subject comprising administering to the subject vardenafil and an enhancer in a ratio of about 20:1 to 2:1 by weight, wherein the enhancer consists of cocamidopropyl betaine, sodium lauroamphoacetate, quaternium-60, isostearamidopropyl morpholine lactate, and dipropylene glycol.
Dependencies are inferred from the claim text.